Lord Hunt of Kings Heath

The Medical Training (Prioritisation) Act 2026 implements the Government’s commitment in the 10-Year Health Plan to prioritise United Kingdom medical graduates for foundation training places, and to prioritise UK medical graduates and other doctors with significant National Health Service experience for specialty training places. This year, at the point of primary allocation, there were more applicants for the 2026 Foundation Programme than places available. This meant that eligible non-prioritised applicants were placed on a national reserve list.

Five rounds of allocation from the reserve list took place between June and August 2026, resulting in 476 applicants being allocated to a Foundation School. Following the final allocation round on 12 August 2026, 188 applicants remained on the reserve list. There are no current plans to run any further rounds to allocate places from the reserve list, nor to fund any additional places on the UK Foundation Programme 2026.

We recognise the potential impact of prioritisation on applicants who are eligible for a foundation training place but do not receive one. The UK Foundation Programme Office aims to be as transparent as possible with affected applicants and provide guidance at every stage of the allocation process.

For individuals who did not secure a Foundation Year 1 post this year, there are alternative routes to pursuing a medical career in the UK. These include obtaining full General Medical Council (GMC) registration through other established GMC pathways, such as completing an approved internship in the country where they trained and then entering the UK healthcare system through applying to a locally employed doctor role or another non-training post.

The Medical Training (Prioritisation) Act 2026 implements the Government’s commitment in the 10-Year Health Plan to prioritise United Kingdom medical graduates for foundation training places, and to prioritise UK medical graduates and other doctors with significant National Health Service experience for specialty training places. This year, at the point of primary allocation, there were more applicants for the 2026 Foundation Programme than places available. This meant that eligible non-prioritised applicants were placed on a national reserve list.

Five rounds of allocation from the reserve list took place between June and August 2026, resulting in 476 applicants being allocated to a Foundation School. Following the final allocation round on 12 August 2026, 188 applicants remained on the reserve list. There are no current plans to run any further rounds to allocate places from the reserve list, nor to fund any additional places on the UK Foundation Programme 2026.

We recognise the potential impact of prioritisation on applicants who are eligible for a foundation training place but do not receive one. The UK Foundation Programme Office aims to be as transparent as possible with affected applicants and provide guidance at every stage of the allocation process.

For individuals who did not secure a Foundation Year 1 post this year, there are alternative routes to pursuing a medical career in the UK. These include obtaining full General Medical Council (GMC) registration through other established GMC pathways, such as completing an approved internship in the country where they trained and then entering the UK healthcare system through applying to a locally employed doctor role or another non-training post.

The Medical Training (Prioritisation) Act 2026 implements the Government’s commitment in the 10-Year Health Plan to prioritise United Kingdom medical graduates for foundation training places, and to prioritise UK medical graduates and other doctors with significant National Health Service experience for specialty training places. This year, at the point of primary allocation, there were more applicants for the 2026 Foundation Programme than places available. This meant that eligible non-prioritised applicants were placed on a national reserve list.

Five rounds of allocation from the reserve list took place between June and August 2026, resulting in 476 applicants being allocated to a Foundation School. Following the final allocation round on 12 August 2026, 188 applicants remained on the reserve list. There are no current plans to run any further rounds to allocate places from the reserve list, nor to fund any additional places on the UK Foundation Programme 2026.

We recognise the potential impact of prioritisation on applicants who are eligible for a foundation training place but do not receive one. The UK Foundation Programme Office aims to be as transparent as possible with affected applicants and provide guidance at every stage of the allocation process.

For individuals who did not secure a Foundation Year 1 post this year, there are alternative routes to pursuing a medical career in the UK. These include obtaining full General Medical Council (GMC) registration through other established GMC pathways, such as completing an approved internship in the country where they trained and then entering the UK healthcare system through applying to a locally employed doctor role or another non-training post.

The Medical Training (Prioritisation) Act 2026 implements the Government’s commitment in the 10-Year Health Plan to prioritise United Kingdom medical graduates for foundation training places, and to prioritise UK medical graduates and other doctors with significant National Health Service experience for specialty training places. This year, at the point of primary allocation, there were more applicants for the 2026 Foundation Programme than places available. This meant that eligible non-prioritised applicants were placed on a national reserve list.

Five rounds of allocation from the reserve list took place between June and August 2026, resulting in 476 applicants being allocated to a Foundation School. Following the final allocation round on 12 August 2026, 188 applicants remained on the reserve list. There are no current plans to run any further rounds to allocate places from the reserve list, nor to fund any additional places on the UK Foundation Programme 2026.

We recognise the potential impact of prioritisation on applicants who are eligible for a foundation training place but do not receive one. The UK Foundation Programme Office aims to be as transparent as possible with affected applicants and provide guidance at every stage of the allocation process.

For individuals who did not secure a Foundation Year 1 post this year, there are alternative routes to pursuing a medical career in the UK. These include obtaining full General Medical Council (GMC) registration through other established GMC pathways, such as completing an approved internship in the country where they trained and then entering the UK healthcare system through applying to a locally employed doctor role or another non-training post.

There is no statutory requirement for psychotherapists and counsellors to be registered with an organisation that holds a voluntary accredited register with the Professional Standards Authority for Health and Social Care (PSA). Organisations that hold registers that are accredited by the PSA are independent, representative bodies and as such, they do not fall under Government oversight. Any decisions about the practise requirements for the professions they represent are a matter for those organisations and their members.

The Government would encourage anyone accessing psychotherapy and counselling services to choose a professional that is a member of a statutorily regulated profession or registered with a voluntary accredited register listed on the PSA website.

The Department has no current plans to extend statutory regulation to the counselling and psychotherapy professions.

Subject to the passage of the Health Bill, specialised services commissioned by integrated care boards (ICBs) will continue to operate within a framework of nationally-set standards, service specifications, and clinical commissioning policies to ensure consistent and equitable access to care across England.

Alongside ICB accountability for commissioning these services, the Department, through its new regional offices, will be responsible for providing oversight and assurance of both the commissioning system and the quality and performance of providers. This will include monitoring against national standards and quality and outcome metrics for different services.

In addition, ICBs will be supported in discharging their new commissioning responsibilities through seven Offices for Pan-ICB Commissioning, which aim to ensure that we maintain a critical mass of expert commissioning knowledge and the capability necessary for the effective and efficient commissioning of these important and complex areas of service provision.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.

The MHRA has plans to gather the currently available evidence on mental health and other related risks for licensed migraine prophylaxis medications, as referenced in the separate responses to questions HL1488 and HL1543. A formal timeline for this review has not yet been agreed, and consequently we are unable to provide an expected completion date at this stage.

The MHRA is committed to communicating any findings that may have implications for patient safety or the safe use of medicines. The MHRA will sometimes issue communications, such as drug safety updates, after the conclusion of a review. However, the review is at an early stage, and it would be premature to comment on any potential communication plans. In addition, any product information changes that may arise as a result of this review would be reflected in the published product information available at locations such as the MHRA website or the Electronic Medicines Compendium website.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.

The MHRA has plans to gather the currently available evidence on mental health and other related risks for licensed migraine prophylaxis medications, as referenced in the separate responses to questions HL1488 and HL1543. A formal timeline for this review has not yet been agreed, and consequently we are unable to provide an expected completion date at this stage.

The MHRA is committed to communicating any findings that may have implications for patient safety or the safe use of medicines. The MHRA will sometimes issue communications, such as drug safety updates, after the conclusion of a review. However, the review is at an early stage, and it would be premature to comment on any potential communication plans. In addition, any product information changes that may arise as a result of this review would be reflected in the published product information available at locations such as the MHRA website or the Electronic Medicines Compendium website.

Clinical reference groups provide expert clinical advice on specialised services and support the development and review of national service specifications and clinical commissioning policies.

The Government recognises the importance of clinical advice and leadership in maintaining high-quality specialised services. Subject to final organisational arrangements, clinical expertise will continue to contribute to the development and review of national standards for specialised services so that commissioning decisions remain informed by the best available evidence and clinical expertise.

Integrated care boards (ICBs) are already subject to statutory duties to involve patients and the public in the planning, development, and consideration of proposals for changes to health services. The Government is committed to ensuring that patients, carers, and the public continue to play a central role in shaping specialised services. The Health Bill proposes to further strengthen local arrangements by making ICBs directly responsible for gathering and acting on patient and public feedback.

Clinicians can ask for access to targeted treatments that are not routinely funded through an Individual Funding Request. Where a treatment is not routinely funded, a clinician can apply to the relevant commissioner on behalf of their patient.

Individual Funding Requests are for exceptional individual cases. They are not intended to provide routine access to treatments for groups of patients.

Government responsibility for delivering brain cancer research is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation (UKRI).

We are committed to furthering our investment in brain cancer research and have already taken steps to stimulate scientific progress and build scientific capacity to do research on brain cancer.

As announced in the National Cancer Plan, investment in the NIHR Brain Tumour Research Consortium, co-funding of the Cancer Research UK Brain Tumour Centres of Excellence, and other direct programmatic spend through NIHR funding streams totals a combined investment of £32.3 million since July 2024, and a total of £45.2 million since 2018, all of which is designed to accelerate brain cancer research.

The total investment in the NIHR Brain Tumour Research Consortium is over £25 million over the course of the awards. This includes an initial £13.7 million investment announced in December 2025, which has been fully contracted. In January 2026, the NIHR announced further investment of a minimum of £11.7 million in the Consortium through funding of work packages. For all work packages, contracting and further payments are contingent upon teams submitting and reviewing detailed costs and, if applicable, agreeing to the suggested amendments and requests for clarification which are currently in progress.

The NIHR’s wider investments in research infrastructure, such as research centres, which run studies, facilities, and services, and the research workforce, leverages research funding from other donors and organisations. These NIHR investments in infrastructure are estimated to be £44.5 million over the period 2018/19 to 2024/25, enabling 298 brain tumour research studies to take place.

Research delivered through UKRI, which includes the Medical Research Council, is the responsibility of the Department for Science, Innovation and Technology. Over six years, from the financial year 2018/19 to 2023/24, UKRI committed £46.8 million to brain tumour research. This is the most recent data we hold.

The NIHR continues to welcome high-quality applications for research into any aspect of human health and care, including brain cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality.

The Government recognises the significant impact cancerous brain tumours can have on patients, carers, and families, and that treatment options remain limited. All new licensed medicines, including for brain cancer, are evaluated by the National Institute for Health and Care Excellence (NICE), which assesses whether they are a clinically and cost-effective use of National Health Service resources.

NICE has recommended vorasidenib for eligible patients aged 12 years old and over with IDH mutant low-grade glioma, as an option for treating grade 2 astrocytoma or oligodendroglioma where it is considered the most suitable treatment. NICE is also actively evaluating further medicines for potential use in brain tumours.

NICE works with companies and the Medicines and Healthcare products Regulatory Agency (MHRA) to issue guidance as close as possible to licensing. The NHS in England must fund medicines recommended by NICE, and the Cancer Drugs Fund can provide access from the point of a draft positive NICE recommendation.

The MHRA recognises the challenges of developing treatments for rare cancers, where large-scale clinical evidence can be difficult to generate, and supports timely access to safe, effective, and high-quality treatments for patients with high unmet need.

The MHRA supports innovative approaches such as precision medicine, real-world evidence, and international collaboration. Relevant routes include Project Orbis, the Access Consortium, the International Recognition Pathway, and the Innovative Licensing and Access Pathway, alongside the Rare Diseases Framework and recent regulations to support faster development of personalised cancer treatments.

Government responsibility for delivering cancer research is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.

The Department of Health and Social Care’s investment in the NIHR facilitates the direct funding of research projects through NIHR programmes, support for researchers to develop and conduct research through NIHR translational infrastructure, and a workforce to deliver research on behalf of other funders through NIHR research delivery infrastructure.

The following table shows the amount the Department, through the NIHR, committed to research for oligodendroglioma, glioblastoma, astrocytoma, and diffuse intrinsic pontine glioma between the financial years 2015/16 to 2024/25:

As NIHR infrastructure primarily funds staff and National Health Service support costs for research delivery, the spend is not directly attributable to specific research studies for the most part, but an estimate is derived based on the number of studies in brain tumour research against the annual infrastructure spend, and is included in the above figures.

The data does fluctuate due to changes such as contract variations and updated information regarding financial reconciliations and support activity.

A breakdown of the percentage of the total research expenditure is not available. This is because much of the NIHR’s investments are for cross-cutting cancer research activities within the NHS and wider health and care system, including research facilities and workforce, known as NIHR infrastructure. In addition, the NIHR cancer research portfolio contains non-specific brain cancer research projects, which will add to the evidence base for the different types of tumours.

The NIHR continues to welcome high-quality applications for research into any aspect of human health and care, including brain cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality.

The National Cancer Plan sets out a whole-system approach to improving outcomes for all cancers, including brain tumours, with a focus on earlier diagnosis, faster access to treatment, research and innovation, patient experience, and survival. The plan's overarching ambition is that three in four people diagnosed with cancer will survive for five years or more by 2035.

The Government is also strengthening support for brain tumour research. In January 2026, the NIHR announced increased investment of more than £25 million in the NIHR Brain Tumour Research Consortium, which aims to accelerate the development of new treatments and improve outcomes for adults and children with brain tumours.

The Department continues to work closely with NHS England, the NIHR, and other partners to deliver the commitments set out in the National Cancer Plan and to support improvements in outcomes for people affected by brain tumours.

Under the Health and Social Care Act 2008, providers of supported accommodation must register with the Care Quality Commission (CQC) if they carry out the regulated activity of ‘personal care’. The Government does not have plans to establish a system to record deaths in supported accommodation that is not registered with the CQC.

However, all supported accommodation providers must comply with their existing legal duties, including meeting the relevant standards for the quality of accommodation.

The local authority must carry out safeguarding enquiries if an adult has care and support needs, whether or not these are being met by the local authority, and is experiencing, or is at risk of, abuse or neglect and, as a result of those needs is unable to protect himself or herself from the abuse or neglect or the risk of it. This also applies to accommodation that is not registered with the CQC.

Safeguarding adults boards must also arrange safeguarding adults reviews in cases where an adult has died or experienced serious harm and there are concerns about how agencies worked together, helping to identify lessons to apply to future cases to prevent deaths or serious harm occurring again.

More broadly, the Government’s Supported Housing (Regulatory Oversight) Act 2023 provides a strong and robust framework which aims to ensure that all residents receive good quality support in good quality accommodation. Under this legislation, housing providers will need to apply for a licence for their supported housing schemes in each local authority, pass a fit and proper person test, and meet several conditions, including complying with the National Supported Housing Standards.

The Government takes the quality and safety of all supported housing very seriously and we are committed to keeping these regulatory arrangements under review to ensure they are effective in preventing avoidable deaths.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.

The MHRA has plans to gather the currently available evidence on mental health and related risks for licensed migraine prophylaxis medications, as referenced in a response to HL1488. Prescribing safety will be considered as part of this review within the scope of the MHRA’s remit. This will include, for example, assessing how prescribing conditions are described in the product information of relevant migraine medicines. However, clinical practice, national or regional clinical guidelines, and a healthcare professional’s decision to prescribe a particular medicine are outside the MHRA’s direct scope of work.

NHS England does not hold information on what mobility devices, including electrically powered wheelchairs, have been adopted for use by the National Health Service in the last five years.

Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchair services and NHS England supports ICBs to commission effective, efficient, and personalised wheelchair services through a range of policies and guidance, including the introduction of personal wheelchair budgets.

Responsibility for providing community equipment to disabled people typically falls to the NHS and local authorities. Local authorities have a statutory duty to make arrangements for the provision of community equipment for disabled people in their area. Types of support include equipment to enable people to live more independently, such as grab rails, walking aids, and wheelchairs for short-term use. Responsibility for managing the market for these services rests with local authorities.

Since July 2015, NHS England has collected quarterly data from clinical commissioning groups, now ICBs, on wheelchair provision, including waiting times, to enable targeted action if improvement is required.

NHS England is supporting ICBs to reduce regional variation in the quality and provision of NHS wheelchairs, and to reduce delays in people receiving timely intervention and wheelchair equipment. This includes publishing a Wheelchair Quality Framework on 9 April 2025, which sets out quality standards and statutory requirements for ICBs, such as offering personal wheelchair budgets. The framework is available at the NHS.UK website and applies to all NHS wheelchair services and provision, including electrically powered wheelchairs.

NHS England introduced personal wheelchair budgets, including legal rights in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided.

I refer the hon. Member to the answer I gave on 30 June 2026 to Questions 1004 to 1007.

As mentioned in those answers, the report Research and development work relating to assistive technology: 2024 to 2025 is updated annually to cover developments in priority setting and funding. The report signposts the public and partners to the full account of research activity.

In the last five available assistive technology reports, covering the financial years 2020/21 to 2024/25, 30 projects were recorded under the primary theme Mobility and Musculoskeletal Health, with a further 15 recorded under that theme as a secondary category. This data has been collated from the published datasets on National Institute for Health and Care Research (NIHR) Open Data, with further information available on the NIHR website. The Department does not currently hold central information on how many of these projects have since reached the National Health Service market.

Responsibility for supporting the development of innovative medical devices and assistive technologies sits across the Government. The Department supports research and innovation through organisations such as the NIHR, which helps generate the evidence needed to support the development, evaluation, and future adoption of health technologies.

The uptake of medical devices within the NHS is primarily a matter for NHS England and local NHS organisations, informed by advice from bodies such as the National Institute for Health and Care Excellence. The Department is working with NHS England, regulators, and industry to address barriers to adoption and to support faster access to clinically effective and cost-effective technologies.

I refer the hon. Member to the answer I gave on 30 June 2026 to Questions 1004 to 1007.

As mentioned in those answers, the report Research and development work relating to assistive technology: 2024 to 2025 is updated annually to cover developments in priority setting and funding. The report signposts the public and partners to the full account of research activity.

In the last five available assistive technology reports, covering the financial years 2020/21 to 2024/25, 30 projects were recorded under the primary theme Mobility and Musculoskeletal Health, with a further 15 recorded under that theme as a secondary category. This data has been collated from the published datasets on National Institute for Health and Care Research (NIHR) Open Data, with further information available on the NIHR website. The Department does not currently hold central information on how many of these projects have since reached the National Health Service market.

Responsibility for supporting the development of innovative medical devices and assistive technologies sits across the Government. The Department supports research and innovation through organisations such as the NIHR, which helps generate the evidence needed to support the development, evaluation, and future adoption of health technologies.

The uptake of medical devices within the NHS is primarily a matter for NHS England and local NHS organisations, informed by advice from bodies such as the National Institute for Health and Care Excellence. The Department is working with NHS England, regulators, and industry to address barriers to adoption and to support faster access to clinically effective and cost-effective technologies.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.

The MHRA has recently received a report relating to the use of migraine medicines and the effect on mental health from a patient. As a result, the MHRA plans to gather the currently available evidence on mental health and related risks for licensed migraine prophylaxis medications and consider whether this suggests a need to update or change existing warnings in the relevant product information. The review would include an assessment of suspected adverse drug reactions recorded within the Psychiatric Disorders System Organ Class in relation to licensed migraine prophylaxis medication use as well as other data sources such as scientific literature.

The MHRA encourages anyone to report if they suspect an adverse reaction to a medical product or products. Further information on Yellow Card reporting is available at the Yellow Card website.

We recognise that the uneven distribution of general practitioners (GPs) is a longstanding, generational challenge which successive administrations have sought to overcome. As we consider future interventions we are looking carefully at lessons from previous approaches, such as Medical Practices Committees, whilst taking account of the current workforce position and contracting landscape within General Practice.

We acknowledge the urgent challenge of ensuring practices facing particular workforce pressures have the resources to continue serving their patients. To address this, we are taking steps to increase capacity in GPs and ensure every practice has the necessary workforce to provide integrated, patient-centred services.

Following stakeholder feedback from the 2026/27 GP Contract consultation, we have introduced a practice-level GP reimbursement scheme using £292 million of repurposed funding from the current Capacity and Access Payment. This funding is available to practices to hire additional GPs or to fund additional sessions with existing GPs to improve access in practices. This aims to strengthen capacity, access, and improve patient satisfaction.

We have also increased flexibility of the Additional Roles Reimbursement Scheme (ARRS) by removing the restriction that ARRS funding can only be used for recently qualified GPs, increasing the maximum reimbursement amount for GP roles to reflect experience, and enabling primary care networks to recruit a broader range of ARRS roles, where agreed with the commissioner.

We recognise the importance of ensuring funding for core GP services is distributed fairly between practices across the country and we know that the current distribution formula is considered outdated. The first phase of a review of the Carr-Hill formula concluded in May and the recommendations are with the Department for consideration.

We are grateful to Parliament for their scrutiny of the Health Bill and look forward to debating any amendments in due course.

I refer the hon. Member to the answer I gave on 30 June 2026 to Questions 1004.

The report Research and development work relating to assistive technology: 2024 to 2025 is updated annually to cover developments in priority setting and funding, current and planned funding schemes, and national action plans or service changes to improve the use of assistive technology.

The Department invests significantly in research through the National Institute for Health and Care Research, the Department's research operational arm. The latest report, covering the period from 1 June 2024 to 31 May 2025, has been produced by the National Institute for Health and Care Research under the direction of the Department.

I refer the hon. Member to the answer I gave on 30 June 2026 to Questions 1004.

The report Research and development work relating to assistive technology: 2024 to 2025 is updated annually to cover developments in priority setting and funding, current and planned funding schemes, and national action plans or service changes to improve the use of assistive technology.

The Department invests significantly in research through the National Institute for Health and Care Research, the Department's research operational arm. The latest report, covering the period from 1 June 2024 to 31 May 2025, has been produced by the National Institute for Health and Care Research under the direction of the Department.

The report Research and development work relating to assistive technology: 2024 to 2025 is updated each year to reflect newly funded research. It is published annually in December, with data curated by the National Institute for Health and Care Research (NIHR) in collaboration with other Government funders.

The report is updated annually to cover developments in priority setting and funding, current and planned funding schemes, and national action plans or service changes to improve the use of assistive technology. It also includes recommendations to inform future assistive technology research and planned work arising from funded projects. The relevant Government funders are responsible for monitoring the projects listed in the report. Ministerial responsibility for monitoring and uptake sits with the Parliamentary Under-Secretary of State for Health Innovation and Safety.

NIHR Open Data is a website managed by the NIHR, the research arm of the Department, to promote the transparency and accessibility of NIHR-funded research.

Since 2023, NIHR Open Data has hosted the Assistive Technologies dataset, which allows funded studies to be filtered by assistive technology research ‘focus areas’. The NIHR does not hold data on how many mobility products have been monitored or subsequently adopted by the National Health Service. The NIHR Open Data dataset is available as supplementary material to the statutory report and can be searched, filtered, and downloaded. Further information is available on the NIHR’s website.

The report Research and development work relating to assistive technology: 2024 to 2025 is updated each year to reflect newly funded research. It is published annually in December, with data curated by the National Institute for Health and Care Research (NIHR) in collaboration with other Government funders.

The report is updated annually to cover developments in priority setting and funding, current and planned funding schemes, and national action plans or service changes to improve the use of assistive technology. It also includes recommendations to inform future assistive technology research and planned work arising from funded projects. The relevant Government funders are responsible for monitoring the projects listed in the report. Ministerial responsibility for monitoring and uptake sits with the Parliamentary Under-Secretary of State for Health Innovation and Safety.

NIHR Open Data is a website managed by the NIHR, the research arm of the Department, to promote the transparency and accessibility of NIHR-funded research.

Since 2023, NIHR Open Data has hosted the Assistive Technologies dataset, which allows funded studies to be filtered by assistive technology research ‘focus areas’. The NIHR does not hold data on how many mobility products have been monitored or subsequently adopted by the National Health Service. The NIHR Open Data dataset is available as supplementary material to the statutory report and can be searched, filtered, and downloaded. Further information is available on the NIHR’s website.